Fig. 8.1 Flowchart of fundamental strategies for the management of epithelial ovarian cancer. Cited from Komiyama et al. [3] with slight modifications 8.2 Surgical Management 8.2.1 Early (Localized to the Ovary)-Staged…
Fig. 7.1 HR-deficient and HR-proficient tumors of high-grade serous ovarian carcinoma [8] HR pathway proficient tumors with CCNE1 amplification were common in primary resistant and refractory cases [7]. Inactivation of…
St Bartholomew’s Hospital trial The Boston study Ref. [9] [10] Published 1996 2003 Design Single arm prospective study Single arm prospective study. Subjects The low-risk asymptomatic women > or = 45 years…
Amount of fibroglandular tissue (FGT) Almost entirely fat Scattered fibroglandular tissue Heterogeneous fibroglandular tissue Extreme fibroglandular tissue Background Parenchymal Enhancement Level Minimal Mild Moderate Marked Symmetric or Asymmetric Focus Masses…
Fig. 15.1 7 T DCE. Invasive ductal carcinoma G2 in a 50-year-old woman at 1 o’clock in the right breast. (a) At DCE MRI of the breast at 7 T…
TX Primary tumor cannot be assessed T0 No evidence of primary tumor Tis Carcinoma in situ Tis (DCIS) Ductal carcinoma in situ Tis (LCIS) Lobular carcinoma in situ Tis (Paget’s)…
Fig. 8.1 Typical timeline of mammographic (MG) findings following Breast Conservation Therapy Early findings of postoperative collections such as seroma and/or hematoma, breast edema and skin thickening, are most pronounced…
Fig. 6.1 (a) Axial STIR with water suppression (silicone sensitive) MRI image showing bilateral intact silicone implants. Signal from the saline component of the phantom (white arrow) is suppressed. High…
Fig. 10.1 Axial and sagittal T1 post contrast images demonstrate an irregularly shaped and irregularly marginated mass with heterogeneous enhancement (arrows). Biopsy demonstrated ER/PR + HER-2- IDC 10.3.2 Her2 Enriched…
Fig. 11.1 Posteriorly located lesion that is not amenable for MRI-guided biopsy. (a) Subtracted sagittal T1W post-contrast image. (b) MRI-directed US from right breast. A 27-year-old woman with BRCA2 gene…
